MA55751A - Composés de 4h-pyrrolo[3,2-c]pyridin-4-one - Google Patents

Composés de 4h-pyrrolo[3,2-c]pyridin-4-one

Info

Publication number
MA55751A
MA55751A MA055751A MA55751A MA55751A MA 55751 A MA55751 A MA 55751A MA 055751 A MA055751 A MA 055751A MA 55751 A MA55751 A MA 55751A MA 55751 A MA55751 A MA 55751A
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyridin
compounds
Prior art date
Application number
MA055751A
Other languages
English (en)
Inventor
Markus Berger
Ulf Bömer
Keith Graham
Heidi Greulich
Bethany Kaplan
Daniel Korr
Matthew Meyerson
Ursula Mönning
Michael Niehues
Jens SCHRÖDER
Volker Schulze
Franziska Siegel
Stephan Siegel
Detlev Sülzle
Original Assignee
Bayer Ag
Dana Farber Cancer Inst Inc
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Dana Farber Cancer Inst Inc, Broad Inst Inc filed Critical Bayer Ag
Publication of MA55751A publication Critical patent/MA55751A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA055751A 2019-04-24 2020-04-22 Composés de 4h-pyrrolo[3,2-c]pyridin-4-one MA55751A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838051P 2019-04-24 2019-04-24
US201962940036P 2019-11-25 2019-11-25

Publications (1)

Publication Number Publication Date
MA55751A true MA55751A (fr) 2022-03-02

Family

ID=70456765

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055751A MA55751A (fr) 2019-04-24 2020-04-22 Composés de 4h-pyrrolo[3,2-c]pyridin-4-one

Country Status (24)

Country Link
US (2) US20220298157A1 (fr)
EP (1) EP3959211B1 (fr)
JP (1) JP7641913B2 (fr)
KR (1) KR102915019B1 (fr)
CN (3) CN117946100A (fr)
AU (1) AU2020262221B2 (fr)
BR (1) BR112021019998B1 (fr)
CA (1) CA3137218A1 (fr)
CL (1) CL2021002770A1 (fr)
CO (1) CO2021014022A2 (fr)
CR (1) CR20210530A (fr)
DO (1) DOP2021000216A (fr)
EC (1) ECSP21077614A (fr)
GE (2) GEAP202415804A (fr)
IL (1) IL287390B2 (fr)
JO (1) JOP20210285A1 (fr)
MA (1) MA55751A (fr)
MX (1) MX2021012987A (fr)
PE (1) PE20220254A1 (fr)
PH (1) PH12021552693A1 (fr)
SG (1) SG11202111304UA (fr)
TW (1) TWI849114B (fr)
UA (1) UA130453C2 (fr)
WO (1) WO2020216781A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
EP3958865B1 (fr) 2019-04-24 2025-12-10 Bayer Aktiengesellschaft Dérivés de 4h-pyrrolo[3,2-c]pyridin-4-one
CN115836070B (zh) * 2020-08-10 2024-08-09 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
US20230364070A1 (en) * 2020-09-23 2023-11-16 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
WO2022094271A1 (fr) * 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Méthodes de traitement du cancer
WO2022098992A1 (fr) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Utilisation de composés macrocycliques dans des méthodes de traitement de cancer
EP4244225A1 (fr) * 2020-11-11 2023-09-20 Bayer Aktiengesellschaft Dérivés de n-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tétrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)éthyl]prop-2-énamide et composés similaires utilisés en tant qu'inhibiteurs d'egfr pour le traitement du cancer
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
CA3217214A1 (fr) * 2021-05-06 2022-11-10 Michael POURDEHNAD Methodes de traitement par n-((r)-1-(3-chloropyridin-2-yl)- 2,2,2-trifluoroethyl)62-((s)-2,6-dioxopiperidin-3-yl)-1- oxoisoindoline-5-carboxamide
IL315739A (en) * 2022-03-24 2024-11-01 Scorpion Therapeutics Inc Methods of synthesizing egfr inhibitors
WO2026047020A1 (fr) 2024-08-28 2026-03-05 Bayer Aktiengesellschaft Formes cristallines d'inhibiteurs de her2/mutegfr et leur procédé de préparation
WO2026047022A1 (fr) 2024-08-28 2026-03-05 Bayer Aktiengesellschaft Forme posologique pharmaceutique solide et stable comprenant une forme cristalline d'un inhibiteur de her2/mutegfr et sa méthode de préparation
CN119264091B (zh) * 2024-09-04 2025-05-27 康龙化成手性医药技术(宁波)有限公司 一种1,5-双取代-3-氧杂双环[3.1.1]庚烷的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US7211573B2 (en) 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
DE102006033140A1 (de) 2006-07-18 2008-01-24 Merck Patent Gmbh Aminoindazolharnstoffderivate
US20100069499A1 (en) 2007-04-27 2010-03-18 Sumitomo Chemical Company, Limited Amide compound and use thereof
ES2424977T3 (es) 2007-08-08 2013-10-10 Glaxosmithkline Intellectual Property Development Limited Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
JP5789602B2 (ja) * 2009-06-15 2015-10-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用
WO2012112363A1 (fr) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Inhibiteurs de cystéine protéases, les cathepsines
WO2015022073A1 (fr) 2013-08-13 2015-02-19 Grünenthal GmbH Pyrroles condensés et leur utilisation en tant qu'inhibiteurs de crac
CN106687457B (zh) * 2014-05-13 2020-01-10 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
US10428044B2 (en) * 2014-06-17 2019-10-01 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
CN107207442A (zh) 2014-12-08 2017-09-26 拜耳医药股份有限公司 新的芳基‑氰基胍化合物
US10301306B2 (en) 2014-12-15 2019-05-28 Bristol-Myers Squibb Company Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors
EA032530B1 (ru) * 2015-01-28 2019-06-28 Байер Фарма Акциенгезельшафт 4h-пирроло[3,2-c]пиридин-4-оновые производные
US11339157B1 (en) * 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives

Also Published As

Publication number Publication date
IL287390B1 (en) 2025-07-01
IL287390B2 (en) 2025-11-01
TWI849114B (zh) 2024-07-21
IL287390A (en) 2021-12-01
WO2020216781A1 (fr) 2020-10-29
ECSP21077614A (es) 2021-11-30
US20250136599A1 (en) 2025-05-01
CN114127064B (zh) 2023-12-26
CO2021014022A2 (es) 2022-03-29
BR112021019998A2 (fr) 2021-12-07
DOP2021000216A (es) 2022-05-15
GEP20247648B (en) 2024-07-25
BR112021019998B1 (pt) 2024-01-16
TW202106683A (zh) 2021-02-16
JP7641913B2 (ja) 2025-03-07
KR20220004103A (ko) 2022-01-11
CL2021002770A1 (es) 2022-05-27
CN114127064A (zh) 2022-03-01
PH12021552693A1 (en) 2022-03-21
CA3137218A1 (fr) 2020-10-29
GEAP202415804A (en) 2024-02-12
CN117946100A (zh) 2024-04-30
CR20210530A (es) 2021-12-23
PE20220254A1 (es) 2022-02-16
JP2022532850A (ja) 2022-07-20
EP3959211B1 (fr) 2026-02-18
KR102915019B1 (ko) 2026-01-21
UA130453C2 (uk) 2026-02-25
SG11202111304UA (en) 2021-11-29
EP3959211A1 (fr) 2022-03-02
MX2021012987A (es) 2022-04-01
AU2020262221B2 (en) 2025-11-20
US20220298157A1 (en) 2022-09-22
JOP20210285A1 (ar) 2023-01-30
AU2020262221A1 (en) 2021-11-18
CN117986251A (zh) 2024-05-07

Similar Documents

Publication Publication Date Title
MA55751A (fr) Composés de 4h-pyrrolo[3,2-c]pyridin-4-one
IL289186A (en) Compounds of 4,4a,5,7,8,8a - hexapyrido[4,3-b][1,4]oxazin-3-one as inhibitors of magl
IL276802A (en) Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidin-3-ones
IL253284A0 (en) History of 4h-pyrrolo[2,3-c]pyridine-4-one
SI4065575T1 (sl) Substituirane triciklične spojine
EP3980010A4 (fr) Composés de pyrazolo[1,5-a]pyrimidine 2,3,5-trisubstitués
IL289233A (en) Compounds 4,4a,5,7,8,8a -hexapyrido[4,3-b][4-1]oxazin-3-one as magl inhibitors
IL272262A (en) Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
IL285315A (en) Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
LT3555097T (lt) Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
IL290445B1 (en) [4,2,1]Triazolo[5,1-c]quinazolin-5-amines
EP3660019C0 (fr) 7h-pyrazolo[3,4-d]triazine-2-oxides en tant qu'explosifs
MA55564A (fr) Composés de pyrrole
IL257413A (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
IL260536B (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
MA54960A (fr) Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine
EP3851439A4 (fr) Inhibiteur de btk contenant du furo[3,4-b]pyrrole
DK3816164T3 (da) Isothiazolo[5,4-d]pyrimidin-forbindelse som irak4-inhibitor
EP3712139A4 (fr) Composés de tétrahydroisoxazolo[4,3-c]pyridine anti-vhb
IL289141A (en) Compounds 7,8 dihydro-4h-pyrazolo[3,4-c]azepin-6-one
EP3640253A4 (fr) Dérivé de 6h-thiéno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazépine
EP4017505A4 (fr) Méthode de modulation de l'adiposité
HK40027677A (en) 1, 2-dihydro-3h-pyrazolo [3, 4-d]pyrimidin-3-one analogs
HK40083238A (en) Substituted straight chain spiro derivatives